Hyaluronic acid-cyclodextrin conjugate encapsulating paeonol for treatment of atopic dermatitis

Posted by

CD was grafted onto hyaluronic acid (HA) to form a topical delivery carrier (HACD) in which Paeonol was loaded in its CD cavity and self-assemble into the polymeric micelles (HACD-PAE) for the treatment of atopic dermatitis. Fluorescence microscope observed that HACD could fast penetrate into the skin and remain stable within 12 h. In vitro penetration test (IVPT) results showed the PAE retentions of HACD-PAE group in the stratum corneum and dermis were 3.35 and 1.78 times improvement than that of PAE group. ATR-FTIR and H&E staining assays indicated HACD could increase the gap of keratinocytes by interacting with corneum lipids and loosening the keratin. Furthermore, HACD-PAE showed the best therapeutic effect on atopic dermatitis mice.

HA was grafted with CD to form an amphipathic polymer HACD, which could not only encapsulate PAE to form polymeric micelles but also improve the drug penetration and retention in the skin. Due to its excellent permeation and retention capacity, the HACD-PAE played a great therapeutically effect on atopic dermatitis of mice. Thus HACD could be a promising skin-specific delivery carrier, not only promoting the drug penetrating, increasing its remaining in the skin and play a role in the skin disease therapy and skin-care.

Yuling Wang, Zeyan Tang, Xueping Guo, Yuqi Zhao, Shujing Ren, Zhenhai Zhang, Huixia Lv (2022) Hyaluronic acid-cyclodextrin encapsulating paeonol for treatment of atopic dermatitis, International Journal of Pharmaceutics 623, 121916. https://doi.org/10.1016/j.ijpharm.2022.121916.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.